Sugi Predict

Sugi Predict / Compounds / SCHEMBL966286

SCHEMBL966286

SCHEMBL966286

NNC(=O)Cc1ccccn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.56
▸ CA2 P00918 1/20 0.56
▸ CA5A P35218 1/20 0.56
▸ CA7 P43166 1/20 0.56
▸ CA5B Q9Y2D0 1/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ GLS O94925 6/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ SIGMAR1 Q99720 1/20 0.48
▸ P2RX7 Q99572 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ PLA2G2A P14555 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29672808 1.00 CA1 (0.56) CA1CA2CA5ACA7CA5B
Hydrochloric Acid SCHEMBL11689290 0.98 CA1 (0.55) CA1CA2CA5ACA7CA5B
SCHEMBL6796071 0.83 PDE5A (0.55) CA1CA2CA5ACA7CA5B
SCHEMBL7814882 0.82 TDP1 (0.55) SMN1; SMN2POLBKDM4ECYP1A2HPGD
SCHEMBL24015947 0.81 SMN1; SMN2 (0.53) CA1CA2CA5ACA7CA5B
SCHEMBL1032275 0.81 SMN1; SMN2 (0.53) CA1CA2CA5ACA7CA5B
SCHEMBL12880515 0.81 L3MBTL1 (0.54) CA1CA2CA5ACA7CA5B
Potassium Ion SCHEMBL11394989 0.80 CA1 (0.55) CA1CA2CA5ACA7CA5B
SCHEMBL10272684 0.80 POLB (0.55) CA1CA2CA5ACA7CA5B
SCHEMBL7817091 0.80 SMN1; SMN2 (0.60) SMN1; SMN2KDM4ECYP1A2HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-10-09 — — US disclosed
US-20250059293-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY INCYTE CORPORATION 2025-02-20 — — US disclosed
US-20250041310-A1 Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors INCYTE CORPORATION 2025-02-06 — — US disclosed
US-20250034153-A1 TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-01-30 — — US disclosed
EP-3541802-B1 ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2025-01-01 — — EP disclosed
US-12110293-B2 Substituted triazolo quinoxaline derivatives Grünenthal GmbH (DE) 2024-10-08 — — US disclosed
US-12060433-B2 CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy INCYTE CORPORATION (US) 2024-08-13 — — US disclosed
CN-117903140-A Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors 因赛特公司 2024-04-19 — — CN disclosed
CN-117500503-A Combination therapy comprising an A2A/A2B inhibitor, a PD-1/PD-L1 inhibitor and an anti-CD 73 antibody 因赛特公司 2024-02-02 — — CN disclosed
US-11873304-B2 Fused pyrimidine derivatives as A2A/A2B inhibitors INCYTE CORPORATION (US) 2024-01-16 — — US disclosed
US-5464830-A ANALGESICS G. D. SEARLE & CO. (US) 1995-11-07 — — US disclosed
US-5391540-A Herbicides ROHM AND HAAS COMPANY (US) 1995-02-21 — — US disclosed
US-5378840-A Substituted dibenzoxazepine compounds G. D. SEARLE & CO. (US) 1995-01-03 — — US disclosed
EP-0583421-A1 SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE G.D. SEARLE & CO. (US) 1994-02-23 — — EP disclosed
EP-0573575-A1 SUBSTITUTED PYRIDINE COMPOUNDS ROHM AND HAAS COMPANY (US) 1993-12-15 — — EP disclosed
US-5228897-A Herbicides MONSANTO COMPANY (US) 1993-07-20 — — US disclosed
WO-1992019617-A2 SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE G.D. SEARLE & CO. (US) 1992-11-12 — — WO disclosed
EP-0512400-A1 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use G.D. Searle & Co. (US) 1992-11-11 — — EP disclosed
WO-1992014711-A1 SUBSTITUTED PYRIDINE COMPOUNDS MONSANTO COMPANY (US) 1992-09-03 — — WO disclosed
US-5125956-A Preemergence herbicides MONSANTO COMPANY (US) 1992-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873304-B2 Fused pyrimidine derivatives as A2A/A2B inhibitors ADORA2A, ADORA2B, ADORA1 CA1 4071/4885CA2 2681/4885CA5A 1961/4885
US-12060433-B2 CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy ADORA2A, ADORA2B, NT5E CA1 2449/4885CA2 2181/4885CA5A 1265/4885
US-20250059293-A1 CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY ADORA2A, ADORA2B, NT5E CA1 2449/4885CA2 2181/4885CA5A 1265/4885
US-20250041310-A1 Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors ADORA2A, ADORA2B, ADORA1 CA1 986/4885CA2 1032/4885CA5A 798/4885
US-20250034153-A1 TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 CA1 3781/4885CA2 2450/4885CA5A 1258/4885
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 CA1 3900/4885CA2 2216/4885CA5A 1193/4885
US-12110293-B2 Substituted triazolo quinoxaline derivatives NR3C1, NR3C2, GRK5 CA1 3877/4885CA2 3220/4885CA5A 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.